Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — UBS 2015 SMID Cap One-on-One Conference
29 slides from Angiodynamics's conference presentation, Aug 5, 2015
Slide 1: UBS 2015 SMID Cap One-on-One Conference
UBS 2015 SMID Cap One-on-One Conference Mark Frost, Executive Vice President & CFOAugust 5, 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, c
Slide 3: Performance Update
Performance Update Next generation AngioVac launched510(k) clearance of a BioFlo Midline catheters Dr. Robert Martin, Director of Surgical Oncology, published NanoKnife abstract in the Annals of Surgery510(k) clearance of NanoKnife System generator and FDA issued Certificates to Foreign Governments
Slide 4: Profile of AngioDynamics
Profile of AngioDynamics Global, leading provider of innovative, image guided, minimally invasive solutions. Three Franchises – Peripheral Vascular, Vascular Access and Oncology/SurgeryFounded 1988 | IPO May 2004—ANGO (NASDAQ)Worldwide presence with 1,300 employees and 7 operating locations, as well
Slide 5: Leadership
Leadership Joseph M. DeVivoPresident & CEO Mark FrostEVP & CFO John SotoEVP & CCO Stephen TrowbridgeSVP & General Counsel Barbara KucharczykSVP, Operations Mark StephensSVP, Administration Gary BarrettSVP, RA/QA * Benjamin DavisSVP, Business Development
Slide 6: AngioDynamics in FY14
AngioDynamics in FY14 * RFA Resection NanoKnife Microwave Venous Ports Dialysis PICCs Other Access Core PV FluidMgmt Sales Growth StdGrossMargin // 100% AngioVac Harvest Fix/Divest Invest Scale FY14 4% Sales Growth; 51% GM Sales by FranchisePeripheral Vascular: $193MVascular Access: $106MOncology/Su
Slide 7: Growth Driver Performance: Our strategy is working
Growth Driver Performance Our strategy is working * 65% FY15 over FY14 BioFlo GROWTH 21% FY15 over FY14 MicrowaveAblation GROWTH 23% FY15 over FY14 AngioVac GROWTH • • • 25% FY15 over FY14 NanoKnife GROWTH Implement near term product family consolidation / elimination opportunitiesTarget Indirect pr
Slide 8: Operational Improvements Plan and Impact
Operational Improvements Plan and Impact Phase 1 - COMPLETE Phase 2 — EXECUTING Phase 3 - PLANNING + Implement near term product family + Site consolidation: + Global distribution strategy iW consolidation / elimination WT PROCESS Saportunlis + Queensbury repurposed as Ww * Assess Global manufacturi
Slide 9: AngioDynamics in FY20
Resection Core PV Dialysis NanoKnife AngioVac PICCs FluidMgmt Ports Other Access Microwave RFA Venous Sales Growth StdGrossMargin High Low AngioDynamics in FY20 FY209% 5YR Sales CAGR; 59% GM Sales by FranchisePeripheral Vascular: ̴$300MVascular Access: ̴$200MOncology/Surgery: ̴$100MTotal: ̴$553M Emb
Slide 10: Strong Product Development Pipeline
Strong Product Development Pipeline* PV VA O/S Celerity X-Ray FY15 BioFlo New Product Launch FY16 Celerity Navigation FY16 BioFlo Port Line Extension FY16 BioFlo PICC Line Extension FY16 Next Generation Radio Frequency Ablation System FY17 Next Generation Microwave Ablation FY16 Next Generation Nano
Slide 11: Clinical Studies
Clinical Studies* SeCure IDE for Expanded EVLT Indication Pancreas Nanoknife Pre-Clinieall CROES II NanoKnife Prostate Study, Prostate NanoKnife IDE Investigator Initiated Trials o/s * LEIDEN —Nanoknife Pancreas + CROES Registry * NEAT —Nanoknife Prostate * CROES Il Nanoknife Prostate + AHPBA Regist
Slide 12: Peripheral Vascular Franchise
Peripheral Vascular Franchise * FY15 Fluid Mgmt. Venous $80 $52 $ in millions $1.6B Market 12% Share Thrombus Mgmt. $15 Other Core Products $45 Total PV $193 YoYGrowth 1% -4% 5% 0% 0% FY14Growth -4% 18% 109% 7% 7%
Slide 13: Thrombus Management Market Summary
Source:Heit JA, et al. Blood. 2005;106:267A.Murphy SL, et al. Deaths: Preliminary Data for 2010. National Vital Statistics Reports; 2012 Thrombus Management Market Summary Additional:Annual Incidence Catheter/Lead RA200,000 RA Mass47,000 IVCF Thrombosis14,000 TV Endocarditis2,500 Surgical Embolectom
Slide 14: Solution: AngioVac
Solution: AngioVac ryone remembers first tir ® angiodynamics Scalable platform for next generation devices Attractive pricing & higher margins FDA deared & CE Mark approved Newly expanded us. indication i>) angiodynamics
Slide 15: Solution: AngioVac
Solution: AngioVac FDA cleared & CE Mark approved Attractive pricing & higher margins Scalable platform for next generation devices Newly expanded U.S. indication *
Slide 16: Vascular Access Franchise
Vascular Access Franchise * FY15 PICCs Ports $48 $35 $ in millions Dialysis $20 Total VA $108 $1.0B Market 11% Share YoY Growth -6% 7% 8% 1% FY14Growth 0% 3% -2% 0%
Slide 17: BioFlo Technology
BioFlo Technology The BioFlo family of products, including PICCs, ports and dialysis catheters, are the only vascular access products manufactured with Endexo Technology, a permanent and non-eluting integral polymer. Less Thrombus Accumulation BioFlo PICCs BioFlo Ports Vs. common PICC Vs. non-coated
Slide 18: Reducing Healthcare Costs
Reducing Healthcare Costs Facility 1 1,251 BioFlo PICCs placed85% reduction in symptomatic UEDVT 7 UEDVTs reported from 1251 PICCsUEDVT rate of .45% versus prior 3.1% Facility 2272 BioFlo PICCs placed42% reduction in Occlusions19.7% reduction in baseline occlusion rate Facility 3776 BioFlo PICCs pla
Slide 19: Celerity Tip Location
Celerity Tip Location Tip location, coupled with our innovative BioFlo Technology, will improve our competitive position in the PICC market. WV Fall 2013 — Canadian Launch Ease of use * Use with existing ultrasound Wi March 6, 2014 — Acquired regulatory control over Celerity platform and rights Clin
Slide 20: Leveraging BioFlo to Win Contracted Business
Leveraging BioFlo to Win Contracted Business The Market ̴30% of ANGO Sales are Contracted AngioDynamics 2 0 1 2 2 0 1 3 2 0 1 4 2 0 1 5 Novation Awards ANGO New Technology Award for BioFlo PICCs8/1/2014 Premier Awards ANGO PICC Contract 7/1/2013 HealthTrust Awards ANGO PICC Contract 1/1/20158/1/2014
Slide 21: Oncology/Surgery Franchise
Oncology/Surgery Franchise * FY15 Thermal Ablation NanoKnife $29 $17 $ in millions Resection/Other $6 Total O/S $52 $225M Market 22% Share YoY Growth -3% 25% 4% 6% FY14Growth 10% 7% -18% 5%
Slide 22: Expanding Leadership in Tissue Ablation
Expanding Leadership in Tissue Ablation THERMAL NON-THERMAL AngioDynamics offers a full complement of tissue ablation products that provide clinicians maximum choice in treating patients. *
Slide 23: Re-Entering the Embolization Market
Re-Entering the Embolization Market On April 9, 2015, AngioDynamics entered an agreement with EmboMedics Inc., which develops injectable & resorbable microspheres and expects to file for U.S. FDA 510(k) clearance for the embolization of hypervascular tumors by January 2016. Novel Technology Hi
Slide 24: International Growth Strategy
International Growth Strategy Market Led, Efficient & Aligned Region-based business model improves competitivenessIncreased direct market expansionNew product introductions and full registration of product portfolioDelivering operating margin improvementAlign talent and organization to ensure consis
Slide 25: Fiscal Fourth Quarter and Full Year Results
Fiscal Fourth Quarter and Full Year Results There is no difference in the number of sales days between the fiscal 2015 and fiscal 2014 periods.Adjusted results exclude costs relating to acquisitions, debt financing, business restructuring, litigation, facility consolidations, amortization of basis s
Slide 26: AngioDynamics Transformation
AngioDynamics Transformation FY11 FY12 FY13 FY14 Net Sales $216M $222M $342M $354M Pro Forma 0% 3% -1%a 4% Exc. BSC/FX – 5% On a pro forma basis prior year sales for AngioDynamics and Navilyst Medical were $344.6 million. Investor Profile – – Major acquisitions – Navilyst (2012), Vortex Medical (201
Slide 27: UBS 2015 SMID Cap One-on-One Conference
UBS 2015 SMID Cap One-on-One Conference Mark Frost, Executive Vice President & CFOAugust 5, 2015
Slide 28: Balance Sheet & Cash Flow
Balance Sheet & Cash Flow $ in millions May 31, 2015 May 31, 2014 Cash & investments $20.1 $17.9 Net working capital $94.7 $85.0 Total assets $773.6 $798.9 Total debt $137.7 $142.7 Total stockholder’s equity $545.0 $536.8 $ in millions, except per share amounts Year ended May 31, 2015 Year ended May
Slide 29: Adjusted Income Statement
Adjusted Income Statement(a) $ in millions, except per share amounts Year ended May 31, 2015 Year ended May 31, 2014 Sales $357.0 $354.4 Gross margins 50.9% 50.7% Operating expenses $141.6 $141.2 Operating income $40.1 $38.7 Operating margin 11.2% 10.9% Net income $21.2 $20.0 EPS $0.58 $0.56 EBITDA
AngioDynamics — UBS 2015 SMID Cap One-on-One Conference on 6ix